title: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
abstract: BACKGROUND
  Both didanosine and zalcitabine are commonly used to treat patients with human immunodeficiency virus (HIV) infection who cannot tolerate zidovudine treatment or who have had disease progression despite it. The relative efficacy and safety of these second-line therapies are not well defined.
  
  
  METHODS
  In this multicenter, open-label trial we randomly assigned 467 patients who previously received zidovudine and had 300 or fewer CD4 cells per cubic millimeter or a diagnosis of the acquired immunodeficiency syndrome (AIDS) to treatment with either didanosine (500 mg per day) or zalcitabine (2.25 mg per day).
  
  
  RESULTS
  After a median follow-up of 16 months, disease progression or death occurred in 157 of 230 patients assigned to didanosine and 152 of 237 patients assigned to zalcitabine, for a relative risk of 0.93 for the zalcitabine group as compared with the didanosine group (P = 0.56), which decreased to 0.84 (P = 0.15) after adjustment for the CD4 count, Karnofsky score, and presence of AIDS at base line. There were 100 deaths in the didanosine group and 88 in the zalcitabine group, for a relative risk of 0.78 (P = 0.09) and an adjusted relative risk of 0.63 (P = 0.003). A majority of patients in each group (66 percent) had at least one adverse event during treatment (153 patients taking didanosine and 157 taking zalcitabine). Peripheral neuropathy and stomatitis occurred more often with zalcitabine and diarrhea and abdominal pain more frequently with didanosine.
  
  
  CONCLUSIONS
  For patients with HIV infection who have not responded to treatment with zidovudine, zalcitabine is at least as efficacious as didanosine in delaying disease progression and death.
authors.affiliation: San Francisco Community Consortium on AIDS, University of California.
authors.forename: D I
authors.initials: DI
authors.lastname: Abrams
authors.forename: A I
authors.initials: AI
authors.lastname: Goldman
authors.forename: C
authors.initials: C
authors.lastname: Launer
authors.forename: J A
authors.initials: JA
authors.lastname: Korvick
authors.forename: J D
authors.initials: JD
authors.lastname: Neaton
authors.forename: L R
authors.initials: LR
authors.lastname: Crane
authors.forename: M
authors.initials: M
authors.lastname: Grodesky
authors.forename: S
authors.initials: S
authors.lastname: Wakefield
authors.forename: K
authors.initials: K
authors.lastname: Muth
authors.forename: S
authors.initials: S
authors.lastname: Kornegay
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D012306:Risk; D016047:Zalcitabine / Q000009:adverse effects / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine